Discovery to Translation: Clinical Trial of a JAK Inhibitor in T1D
A Breakthrough T1D-funded clinical trial will test if a JAK inhibitor will preserve beta cell function in children and young adults with recently diagnosed T1D.
What If You Could Halt Immune Cell Memory?
JDRF-funded researchers have discovered a protein on immune cells that, when it is disabled, could halt immune cell memory.
How Type 1 Diabetes was Established as an Autoimmune Disease
In 1974, two teams showed that diabetes is associated with antibodies against beta cells, which helped establish T1D as an autoimmune disease.
The Power of the Patient Voice: Breakthrough T1D Video
In the words of Colin Dayan, M.D., Ph.D., professor of clinical diabetes and metabolism at Cardiff University: “Type 1 diabetes is almost the only major autoimmune disease now that does not have a licensed immunotherapy.” And he’s going to change that.
Updates from the Teplizumab Trial: You’re Not Going to Believe the Results
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two years—the onset of type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of […]
Dr. Carla Greenbaum Talks about T1D TrialNet During the COVID-19 Pandemic
Carla Greenbaum, M.D., chair of TrialNet—an international Breakthrough T1D-supported network that is dedicated to finding cures for type 1 diabetes (T1D)—and a professor at Benaroya Research Institute, discussed T1D research in the time of COVID-19, including what TrialNet is up to, on Breakthrough T1D’s Facebook Live event. She chats about: What do we know now […]
New Research Suggests that T1D Has Two Distinct Types
Breakthrough T1D-funded researchers found that type 1 diabetes is comprised of two different subtypes, called endotypes, which are dependent upon the age at diagnosis.
